Weekly Funding Opportunities

[Med Research]

Children's Heart Foundation: Congenital Heart Defect Research<https://urldefense.com/v3/__https://www.childrensheartfoundation.org/for-researchers/__;!!PhOWcWs!ktv4byGvB8C7fzkR1-y_gYr9ifkK5EIUeMJujW0zcqgoshKscnMiAjM3-kNcvSkGlzELNPSCB9pmd_TWZw0$ >
CHF seeks to fund life-saving, life-changing CHD research in clinical cardiology, basic science, population science, and advancement of surgical/interventional techniques, including, but not limited to the following areas:

  *   Genetics
  *   Biochemistry
  *   Pharmacology
  *   Devices and procedural research (cardiac catheterization and surgery)
  *   Neurodevelopmental and functional outcomes
  *   Quality and policy regarding delivery of care, coverage, and access
  *   Maternal environment and modifiable disease impact on fetuses with CHD
  *   Fetal diagnosis and intervention
  *   Long-term care of adults with CHDs
  *   Technological development and advancements
$100,000 for 1-2 year projects, no IDC.
Due June 5, 2020. Med-RA deadline to receive draft documents: May 26.

Vilcek Prizes For Creative Promise in Biomedical Science<https://urldefense.com/v3/__https://vilcek.org/prizes/vilcek-prizes-for-creative-promise/__;!!PhOWcWs!ktv4byGvB8C7fzkR1-y_gYr9ifkK5EIUeMJujW0zcqgoshKscnMiAjM3-kNcvSkGlzELNPSCB9pmr4mdZK0$ >
Three unrestricted cash prizes of $50,000 each will be awarded to young foreign-born biomedical scientists who demonstrate outstanding early achievement in basic, applied, and/or translational biomedical science. Applicants must have earned a doctoral degree (MD, PhD, or equivalent) and should hold full-time positions at an academic institution or other organization, including positions of assistant or associate professor, or equivalent independent position. To be eligible, applicants must have been born outside the United States; be no older than age 38 as of December 31, 2020 (born on or after January 1, 1982); be a naturalized citizen or permanent resident (green card holder) of the United States; be a holder of an H1B or O-1 visa and have been living and working in the United States for at least five years; or have been granted Deferred Action for Childhood Arrivals (DACA) relief.
Due June 10, 2020. Med-RA deadline to receive draft documents: May 28.

Neuroendocrine Tumor Research Foundation: Research Grants<https://urldefense.com/v3/__https://netrf.org/for-researchers/funding-for-researchers/__;!!PhOWcWs!ktv4byGvB8C7fzkR1-y_gYr9ifkK5EIUeMJujW0zcqgoshKscnMiAjM3-kNcvSkGlzELNPSCB9pmNsPZ5kE$ >
The Neuroendocrine Tumor Research Foundation (NETRF) is inviting applications for innovative research with the potential to increase the basic understanding of these uncommon tumors and lead to the development of more effective therapies. Grants ranging between $100,000 to $1.2 million will be awarded in support of projects over one to four years in the areas of basic, translational, or clinical neuroendocrine cancer research. Four different grants will be awarded:

  *   Accelerator Award — Grants of up to $1.2 million over four years will be awarded to projects that bring together investigators from diverse scientific disciplines.
  *   Investigator Awards — Grants of up to $300,000 over two years will be awarded to investigators and teams with the tools to study neuroendocrine cancers in innovative and transformative ways.
  *   Pilot Awards — Grants of up to $100,000 over one year will be awarded for pilot studies.
  *   Mentored Awards — Grants of up to $120,000 over two years will be awarded to encourage early-career investigators to pursue neuroendocrine tumor research and make a commitment to the field.
Areas of interest include but are not limited to application of existing or new technologies to target NETs; new/optimized experimental models; cancer metabolism; deciphering the molecular underpinnings of NETs; diagnostics; clinical research, cell invasion and metastasis; immune microenvironment; and nuclear medicine, theranostics, and/or imaging. NETRF also invites proposals that cover promising and potentially transferable technologies that have been applied successfully to other areas of cancer. While NETRF recognizes that neuroendocrine cancers can develop in many different organs, the focus of this RFP includes gastro-entero-pancreatic NETs, including sites of metastasis, and lung carcinoids.
Due June 12, 2020. Med-RA deadline to receive draft documents: June 1.

Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (R01)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HS-20-003.html__;!!PhOWcWs!ktv4byGvB8C7fzkR1-y_gYr9ifkK5EIUeMJujW0zcqgoshKscnMiAjM3-kNcvSkGlzELNPSCB9pmaRvCdpE$ >
This Funding Opportunity Announcement (FOA) invites R01 grant applications for funding to support novel, high-impact studies evaluating the responsiveness of healthcare delivery systems, healthcare professionals, and the overall U.S. healthcare system to the COVID-19 pandemic. AHRQ is interested in funding critical research focused on evaluating topics such as effects on quality, safety, and value of health system response to COVID-19; the role of primary care practices and professionals during the COVID-19 epidemic; understanding how the response to COVID-19 affected socially vulnerable populations and people with multiple chronic conditions; and digital healthcare including innovations and challenges encountered in the rapid expansion of telehealth response to COVID-19. AHRQ encourages multi-method, rapid-cycle research with the ability to: produce and disseminate initial findings (e.g. observations, lessons learned, or findings) within 6 months after award and then regularly throughout the remainder of the award period.
Due June 15, 2020. Med-RA deadline to receive draft documents: June 2.

Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-019.html__;!!PhOWcWs!ktv4byGvB8C7fzkR1-y_gYr9ifkK5EIUeMJujW0zcqgoshKscnMiAjM3-kNcvSkGlzELNPSCB9pmXTASXfw$ >
To support generation of single cell RNA-sequencing data sets for at least one brain region relevant to persistent HIV infection and opioid, cocaine and/or methamphetamine use disorder.
Due July 20, 2020. Med-RA deadline to receive draft documents: July 7.

NINDS Research Program Award (R35, Outstanding Investigator Award, Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-030.html__;!!PhOWcWs!ktv4byGvB8C7fzkR1-y_gYr9ifkK5EIUeMJujW0zcqgoshKscnMiAjM3-kNcvSkGlzELNPSCB9pmkuu1pxE$ >
The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased freedom and flexibility to Program Directors (PDs)/Principal Investigators (PIs) to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor trainees, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI’s recent NINDS support (Part 2, Section II). This greater funding stability will provide eligible investigators increased security, allowing them to undertake research projects that require a longer timeframe or to embark upon research that breaks new ground. Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center, will not be considered through this program. Benefits of the RPA include:
• A more stable funding environment, facilitating the pursuit of longer-term research goals;
• Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims;
• Reduced time spent writing grant applications and managing multiple grant awards, allowing investigators to spend more time conducting and overseeing research; and
• More time for PDs/PIs to mentor and train individuals in their laboratories.
Enhancing the diversity and inclusiveness of the neuroscience and biomedical research workforce will enhance our overall creativity and ability to expand fundamental knowledge about the brain and nervous system and contribute to reducing the burden of neurological disease. The RPA is a signature program for NINDS, as such NINDS strives to ensure it reflects our commitment to diversity. As scientific progress accelerates by leveraging a broad range of experiences, NINDS strongly encourages women and individuals from diverse backgrounds (including nationally underrepresented groups) to apply.
Due July 31, 2020. Med-RA deadline to receive draft documents: July 20.

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-20-207.html__;!!PhOWcWs!ktv4byGvB8C7fzkR1-y_gYr9ifkK5EIUeMJujW0zcqgoshKscnMiAjM3-kNcvSkGlzELNPSCB9pmddXMr2g$ >
The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.
Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for August 12 standard date: July 30.

HIV Infection of the Central Nervous System (R01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-20-149.html__;!!PhOWcWs!ktv4byGvB8C7fzkR1-y_gYr9ifkK5EIUeMJujW0zcqgoshKscnMiAjM3-kNcvSkGlzELNPSCB9pmr4z6rNQ$ >
The goals of this Funding Opportunity Announcement (FOA) are to stimulate further research on delineating the pathophysiology of HIV-1 associated CNS disease in the setting of chronic viral suppression and ART. In addition, FOA also encourages research studies to aid in the identification/ validation of biomarkers and pre-clinical targets with quantifiable readouts in domestic and international settings. Multidisciplinary research teams and collaborative alliances are encouraged but not required.
Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for September 7 standard date: August 25.

Eradication of HIV-1 from Central Nervous system Reservoirs (R01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/pa-20-151.html__;!!PhOWcWs!ktv4byGvB8C7fzkR1-y_gYr9ifkK5EIUeMJujW0zcqgoshKscnMiAjM3-kNcvSkGlzELNPSCB9pmmX-OV9s$ >
This Funding Opportunity Announcement invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system in the context of viral suppression. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.
Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for September 7 standard date: August 25.

Congressionally Directed Medical Research Programs
Hearing Restoration Research Program<https://urldefense.com/v3/__https://cdmrp.army.mil/funding/hrrp__;!!PhOWcWs!ktv4byGvB8C7fzkR1-y_gYr9ifkK5EIUeMJujW0zcqgoshKscnMiAjM3-kNcvSkGlzELNPSCB9pmzP1fnhg$ >
Focused Research Award
Pre-application (prepropsal): July 14, 2020. Application: November 3, 2020. Med-RA deadline to receive draft documents for July 14 preproposal deadline: July 7.
Kidney Cancer Research Program<https://urldefense.com/v3/__https://cdmrp.army.mil/funding/kcrp__;!!PhOWcWs!ktv4byGvB8C7fzkR1-y_gYr9ifkK5EIUeMJujW0zcqgoshKscnMiAjM3-kNcvSkGlzELNPSCB9pmsX4bY5g$ >
Academy of Kidney Cancer Investigators – Early Career Investigator Award
Pre-application (letter of intent): August 5, 2020. Application: August 26, 2020. Med-RA deadline to receive draft documents for August 5 letter of intent deadline: July 27.
Concept Award
Pre-application (letter of intent): July 15, 2020. Application: August 5, 2020. Med-RA deadline to receive draft documents for July 15 letter of intent deadline: July 6.
Translational Research Partnership Award
Pre-application (letter of intent): August 5, 2020. Application: August 26, 2020. Med-RA deadline to receive draft documents for August 5 letter of intent deadline: July 6.
Prostate Cancer Research Program<https://urldefense.com/v3/__https://cdmrp.army.mil/funding/prorp__;!!PhOWcWs!ktv4byGvB8C7fzkR1-y_gYr9ifkK5EIUeMJujW0zcqgoshKscnMiAjM3-kNcvSkGlzELNPSCB9pmxJ4MN3M$ >
Prostate Cancer Pathology Resource Network Award
Pre-application (letter of intent): September 10, 2020. Application: September 24, 2020. Med-RA deadline to receive draft documents for September 10 letter of intent deadline: August 31.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20200518/6ff3c626/attachment.html>